Stockwatch

Date	Sym	Type	Headline
2024-04-18 16:05	UU:VSTM	News Release200	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
2024-04-04 07:30	UU:VSTM	News Release200	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 07:00	UU:VSTM	News Release200	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
2024-03-14 16:05	UU:VSTM	News Release200	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
2024-03-11 07:30	UU:VSTM	News Release200	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
2024-03-05 17:27	UU:VSTM	News Release200	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2024-03-05 16:30	UU:VSTM	News Release200	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
2024-01-29 07:00	UU:VSTM	News Release200	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
2024-01-18 16:00	UU:VSTM	News Release200	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
2024-01-11 07:00	UU:VSTM	News Release200	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
2024-01-05 07:00	UU:VSTM	News Release200	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-18 07:00	UU:VSTM	News Release200	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
2023-12-13 07:00	UU:VSTM	News Release200	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2023-11-13 07:00	UU:VSTM	News Release200	New Healthcare Professional Component of Let ¢ € ™s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
2023-11-08 16:12	UU:VSTM	News Release200	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-11-07 07:00	UU:VSTM	News Release200	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer
2023-11-06 07:00	UU:VSTM	News Release200	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population
2023-10-26 16:05	UU:VSTM	News Release200	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments
2023-10-18 16:50	UU:VSTM	News Release200	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-10-14 12:30	UU:VSTM	News Release200	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS ¢ „ ¢ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer
2023-10-06 07:00	UU:VSTM	News Release200	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-28 14:15	UU:VSTM	News Release200	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
2023-09-05 07:00	UU:VSTM	News Release200	Verastem Oncology to Participate in Upcoming Investor Conferences
2023-08-28 07:00	UU:VSTM	News Release200	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers
2023-08-08 16:05	UU:VSTM	News Release200	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-07-11 07:00	UU:VSTM	News Release200	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
2023-07-10 16:05	UU:VSTM	News Release200	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-07-05 16:05	UU:VSTM	News Release200	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
2023-05-31 09:11	UU:VSTM	News Release200	Verastem Oncology Announces Reverse Stock Split
2023-05-25 17:05	UU:VSTM	News Release200	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
2023-05-16 07:00	UU:VSTM	News Release200	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
2023-05-09 16:05	UU:VSTM	News Release200	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress